Home > Boards > US Listed > Biotechs > HEAT BIOLOGICS INC (HTBX)

Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Paraceratherium Member Profile
 
Followed By 0
Posts 230
Boards Moderated 0
Alias Born 06/29/17
160x600 placeholder
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 6/4/2019 5:02:01 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/3/2019 2:41:31 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/3/2019 7:32:36 AM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 5/22/2019 4:53:03 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/15/2019 7:52:28 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/15/2019 7:46:36 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/7/2019 9:02:10 AM
Amended Annual Report (10-k/a) Edgar (US Regulatory) - 4/24/2019 5:09:01 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/18/2019 5:06:44 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/18/2019 5:01:25 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/4/2019 6:02:57 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 4/4/2019 6:02:22 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/2/2019 8:17:11 AM
Annual Report (10-k) Edgar (US Regulatory) - 3/28/2019 7:48:23 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/28/2019 7:36:45 AM
Amended Securities Registration (section 12(b)) (8-a12b/a) Edgar (US Regulatory) - 3/13/2019 6:08:07 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/12/2019 8:01:46 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/28/2019 5:53:55 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/28/2019 2:39:21 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/25/2019 5:05:10 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2019 2:21:49 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2019 1:43:46 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/14/2019 4:32:38 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/10/2019 4:32:08 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/8/2019 4:31:47 PM
Paraceratherium   Monday, 02/25/19 10:39:01 PM
Re: None
Post # of 2985 
Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing therapies designed to activate a patient's immune system against cancer, today announced that it has dosed its first patient in its Phase 2 clinical trial investigating HS-110 in combination with Merck's anti-PD1 checkpoint inhibitor, KEYTRUDA® (pembrolizumab), in patients with advanced non-small cell lung cancer (NSCLC). This expansion of the Company's Phase 2 trial into first-line maintenance treatment with Keytruda follows positive interim results reported last year on previously treated patients receiving HS-110 in combination with Bristol-Myers Squibb's anti-PD-1 checkpoint inhibitor, Opdivo® (nivolumab).

Bristol-Myers Squibb Company (BMS) is an American pharmaceutical company, headquartered in New York City.

Bristol-Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.

Could be Bristol-Myers Squibb-Heat one day.......stay tuned.....Bristol-Myers is running on the inside track.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist